← Therapy pipeline
Investigational · Obesity development

HM15275

LA-GLP/GIP/GCG · Hanmi Pharmaceutical

Weekly GLP-1/GIP/glucagon tri-agonist; Phase 2 is testing weight change and lean-mass outcomes.

GLP-1GIPglucagon
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorHanmi Pharmaceutical
TargetsGLP-1 + GIP + glucagon
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

Phase 1 · sponsor-reportedMean body-weight changeBody weight decreased 4.8% · Four weekly doses · Phase 1
Phase 1 · Injection · Sponsor-reported numerical results

Mean body-weight change · Four weekly doses

Study focus: Weight management

Investigational regimen
4.8%

Participants with obesity or overweight; detailed population not provided in the cited summary · Highest tested dose sequence; source summary does not give the dose · N not included in this summary · Sponsor-reported; Phase 1. Results & methods ↗

Early sponsor-reported result after four doses; not a Phase 2 efficacy result. Detailed dose, denominator, and analysis were not included in the referenced update.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagonTargeted
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 2U.S. obesity Phase 2 active
Milestone → next

Latest: First participant dosed in the U.S. obesity Phase 2 in December 2025.

Next: Phase 2 completion is expected in the first half of 2027.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies2 records

Phase 2

U.S. obesity Phase 2 · NCT07205900

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

36-week study of obesity and severe obesity; weight and lean-mass outcomes.